---
title: 'Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular
  atrophy: a prospective European multinational observational study'
date: '2024-02-16'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38361750/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240216170700&v=2.18.0
source: heidelberg[Affiliation]
description: 'BACKGROUND: Evidence for the efficacy of nusinersen in adults with 5q-associated
  spinal muscular atrophy (SMA) has been demonstrated up to a period of 16 months
  in relatively large cohorts but whereas patients reach a plateau over time is still
  to be demonstrated. We investigated the efficacy and safety of nusinersen in adults
  with SMA over 38 months, the longest time period to date in a large cohort of patients
  from multiple clinical ...'
disable_comments: true
---
BACKGROUND: Evidence for the efficacy of nusinersen in adults with 5q-associated spinal muscular atrophy (SMA) has been demonstrated up to a period of 16 months in relatively large cohorts but whereas patients reach a plateau over time is still to be demonstrated. We investigated the efficacy and safety of nusinersen in adults with SMA over 38 months, the longest time period to date in a large cohort of patients from multiple clinical ...